Agile Therapeutics, Inc. (NASDAQ:AGRX) Chairman Alfred Altomari acquired 10,000 shares of the company’s stock in a transaction on Friday, August 25th. The stock was acquired at an average price of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the purchase, the chairman now owns 161,587 shares of the company’s stock, valued at approximately $539,700.58. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) opened at 3.38 on Wednesday. The stock’s market cap is $97.36 million. Agile Therapeutics, Inc. has a 12-month low of $1.82 and a 12-month high of $7.95. The company’s 50-day moving average is $3.95 and its 200-day moving average is $3.33.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. During the same period in the prior year, the firm earned ($0.29) earnings per share. On average, analysts expect that Agile Therapeutics, Inc. will post ($1.03) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/30/alfred-altomari-acquires-10000-shares-of-agile-therapeutics-inc-agrx-stock.html.

A number of research firms have commented on AGRX. Janney Montgomery Scott restated a “buy” rating and issued a $13.00 price objective (down from $15.00) on shares of Agile Therapeutics in a research note on Thursday, August 24th. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. HC Wainwright started coverage on shares of Agile Therapeutics in a research note on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target on the stock. Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Sunday, July 16th. Finally, ValuEngine upgraded shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $8.75.

Several hedge funds have recently made changes to their positions in AGRX. Royce & Associates LP boosted its stake in shares of Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock worth $3,745,000 after buying an additional 11,000 shares during the period. Royal Bank of Canada boosted its stake in shares of Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 27,907 shares during the period. Janney Montgomery Scott LLC bought a new stake in shares of Agile Therapeutics during the second quarter worth approximately $122,000. Renaissance Technologies LLC boosted its stake in shares of Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 43,300 shares during the period. Finally, Susquehanna International Group LLP bought a new stake in shares of Agile Therapeutics during the second quarter worth approximately $205,000. 67.59% of the stock is owned by institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.